Ashley Gallagher, Associate Editor

The company-sponsored phase 1/2 study evaluates a cryopreserved, readily available formulation for the treatment of follicular and diffuse large B cell lymphomas.

Health care providers’ recommendations will make a difference, results of a new poll from the University of Michigan show.

Topline results from the KarMMa-3 trial show that idecabtagene vicleucel significantly improves progression-free survival vs standard regimens.

Approximately 6000 participants aged 5 years and older at 50 sites in different countries are set to received 3 doses of VLA 15 µg or the saline placebo, followed by a booster.

The interim analysis of the TROPION-Lung02 trial demonstrate an overall response rate of 37% in individuals who were treated with datopotamab deruxtecan and pembrolizumab.

Analysis supports positive lifestyle habits, such as exercising and quitting smoking, investigators say.

Investigators from NYU’s Grossman School of Medicine sound alarm on treatment gap and suggest ways to remove barriers, as opioid overdoses soar to historic levels.

Study suggests that health care providers should discuss with patients whether they are using any integrative medicine strategies, which ones, and why.

The approval is based on results of the phase 3 study, ARASENS, that demonstrated a statistically significant increase in overall survival, the trial’s primary endpoint.

Preliminary data from the ongoing dose-escalation portion of the clinical trial, show dose-dependent anti-tumor activity when combined with standard-dose Libtayo.

Unlike prior recommendations for prevention, which focus on dietary factors associated with first-time stone formulation, the new analysis looks at recurrences.

Revised plan incorporates lessons from the COVID-19 pandemic and recent advances in technology, aligning with the Department of Health and Human Services’ roadmap.

The median overall survival of the lenvatinib monotherapy arm is longer than that observed in previous clinical trials evaluating it as a monotherapy for unresectable hepatocellular carcinoma.

The B-Clear study investigated the efficacy and safety of 12- or 24-weeks treatment with bepirovirsen in individuals with chronic hepatitis B.

Investigators found that the health risks linked to the condition known as metabolic syndrome could be diminished by green tea’s anti-inflammatory benefits in the gut.

Older individuals who were exposed to any amount of light while sleeping were significantly more likely to be obese, have high blood pressure, and have diabetes.

A recent study found that 61% of otherwise healthy Black and Hispanic adolescents have low vitamin D levels, which continues to drop with age.

Results also show that nearly half are not sure whether a vaccine exists, and a large majority know that the disease spreads through close contact.

Study is the first to use an artificial intelligence algorithm to break down visual field loss in new-onset glaucoma cases among population groups in the United States.

The effective preventive treatment could reduce HIV rates but needs greater access and affordability, especially among Black and Latino populations, investigators contend.

Driving distance is not a predictor of accessibility for those who do not have a car or access to public transportation, investigators say.

If approved the drug will be the first allogeneic advanced stem cell therapy donor source for patients with blood cancers.

The next-generation vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain and an Omicron variant.

IMscin001 analysis shows non-inferior levels of the cancer immunotherapy in the blood compared with intravenous infusion in individuals with advanced non–small cell lung cancer.

Submissions are based on 3 phase 3 clinical trials showing that the drug achieved the co-primary endpoints of clinical remission and endoscopic response as induction and maintenance treatment.

Investigators found that treatment of high-grade squamous intraepithelial lesions in patients with HIV reduced anal cancer incidence by approximately 57%.

The findings of the phase 1b/2 CHRYSALIS-2 cohort will be presented at the International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer.

The immune responses to the Omicron variant waned substantially with neutralizing antibody levels decreasing 2.4- to 5.3-fold by 3 months after the booster dose.

Currently, there is no treatment targeted for superoxide dismutase 1 amyotrophic lateral sclerosis, which has a life expectancy of 3 to 5 years from time of symptom onset.

After a second booster dose, efficacy against COVID-19 Omicron subvariants rose to 80% within the first 6 months, according to results of a study by the CDC.